Evaluation of limb function after treatment with chemotherapy and carbon ion radiotherapy for Ewing sarcoma of the scapula: A report of three cases Authors: Noriko Kato, Takashi Yanagawa, Masahiko Okamoto, Tatsuya Ohno, Hirotaka Chikuda Published: 2026 ABSTRACT Ewing sarcoma is a rare malignant tumor that tends to occur in children and adolescents; it usually arises from the pelvis and extremities, whereas it rarely originates from the scapula. The present study describes the treatment of three patients with Ewing sarcoma of the scapula using chemotherapy and carbon ion radiotherapy (CIRT), evaluating their oncological outcome and shoulder function. Three patients with Ewing sarcoma of the scapula were treated at the Gunma Prefectural Cancer Center (Ota, Japan) and Gunma University Heavy Ion Medical Center (Maebashi, Japan) with chemotherapy and CIRT. Case 1 was a 75-year-old man who presented with a scapular lesion infiltrating the anterior, posterior and superior aspects. A total of 2 years and 6 months after treatment, the patient showed no evidence of the disease, although they had a limited range of motion in their shoulder and a Musculoskeletal Tumor Society (MSTS) score of 70%. Case 2 was a 40-year-old man who presented with a scapular tumor invading the anterior and posterior aspects, while sparing the subacromial space and glenohumeral joints. A total of 2 years and 6 months after treatment, the patient remained disease-free with an MSTS score of 87%. Case 3 was a 32-year-old woman who presented with a scapular lesion that extended into the infraspinatus and latissimus dorsi muscles, and with multiple lung metastases. During treatment, the patient experienced radiation recall dermatitis, which was treated with opioids and steroids. A total of 3 years after treatment, the patient had an excellent range of motion in the shoulder joint, with an MSTS score of 87%, although lung metastases persisted. In conclusion, CIRT may be considered an acceptable treatment modality for Ewing sarcoma of the scapula and may possibly be used as an alternative to surgery. Introduction Ewing sarcoma is a rare and aggressive cancer primarily affecting children and adolescents. It typically arises in the pelvis or long bones. Scapular involvement is observed in only 3–4% of cases (1,2). Consequently, a few reports have described the clinical characteristics and long-term outcomes. These have indicated that scapular involvement is predominantly observed in males (52–59%), with an average age at diagnosis of 16–17.6 years, and a 5-year survival rate of 68–71.4%, consistent with previous studies for other sites (1,3). Multimodal treatment has significantly increased 5-year overall survival in localized Ewing sarcoma from <10% in the pre-chemotherapy era to approximately 70–80% today (4–6). To achieve adequate local control, definitive surgery has been performed for malignant tumors; however, total scapulectomy for scapular lesions is associated with a loss of shoulder function [Musculoskeletal Tumor Society (MSTS) scores 40–70%] (7). Ewing sarcoma is known to be radiosensitive. However, the local failure rate for Ewing sarcoma with radiotherapy alone is 15–35% which seems to be unsatisfactory (8,9). In the past two decades, carbon ion radiotherapy (CIRT) has been used for unresectable or hard-to-excise bone and soft-tissue sarcomas because of its physical and biological advantages over X-ray radiotherapy, in terms of higher dose localization properties and higher cell-killing effects (10,11). In addition, Bragg peak and high biological effectiveness of CIRT allows for hypofractionated schedule and a short treatment course compared to X-ray radiotherapy (12). Given its properties, CIRT appears to be a more suitable modality than conventional radiotherapy for treating scapular Ewing sarcomas located close to important neurovascular bundles, thereby offering better disease control while minimizing side effects. We report three cases of scapular Ewing sarcoma treated with CIRT and evaluate their oncological and functional outcomes. Case report All three patients were diagnosed with Ewing sarcoma, received chemotherapy, were followed up at the Gunma Prefectural Cancer Center (Ota, Japan), and were treated with CIRT at the Gunma University Heavy Ion Medical Center (Maebashi, Japan). The details of the CIRT procedure have been reported previously (13). Briefly, the patients were treated with CIRT [total dose: 67.2 Gy (relative biological effectiveness)] in 16 fractions, once a day, 4 days a week. The clinical target volume (CTV) included the gross tumor volume and suspected microscopic extensions derived from planning computed tomography (CT) with the assistance of Gd-enhanced diffusion magnetic resonance imaging (MRI) and positron emission tomography (PET)-CT. Subsequently, a 5-mm margin was added to the CTV to define the Planning target volume. CIRT was performed at least four weeks after the last dose of chemotherapy. Dose constraints were not required for the ribs and lungs in the three cases because the affected areas were small. A constraint was applied to the nerves, limiting the dose to the most exposed 1 cm3 (D1 cm3) to ≤50 Gy (RBE). Case 1 A 75-year-old man, without any significant medical history, presented to our hospital with persistent right shoulder pain in July 2023. On examination, he had severe shoulder pain with swelling and slight local heat and could not actively move his shoulder. MRI revealed a tumorous lesion in the right scapula, infiltrating the anterior and posterior aspects and the subacromial space (Fig. 1A and B). Positron emission tomography-computed tomography (PET-CT) showed a high maximum standardized uptake value (SUVmax) of 37.9 in the scapular lesion (Fig. 1C) and multiple pulmonary metastases. After being diagnosed with Ewing sarcoma, he received the VDC-IE chemotherapy (vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide). After three cycles, the multiple lung metastases nearly disappeared, prompting us to treat the scapular lesion with CIRT. The patient received three additional chemotherapy cycles followed by CIRT. After two more chemotherapy cycles, chemotherapy was halted due to prolonged pancytopenia and severe febrile neutropenia. At the end of treatment, PET-CT indicated a reduction in SUVmax to 3.59 in the local lesion and complete disappearance of pulmonary metastases. At two years post-treatment, there were no signs of local relapse or metastasis on MRI (Fig. 1D) and PET-CT, although scapular destruction persisted. He had a limited range of motion of the right shoulder (flexion, 40°; extension, 10°; abduction, 20°; external rotation, 0°; MSTS score, 70%). Case 2 A 40-year-old man presented to our hospital with a tumor on his left scapula, with shoulder pain, and swelling 3 months prior to his first visit in August 2023. The patient was diagnosed with Hodgkin's lymphoma at 25 years of age and treated with chemotherapy that included doxorubicin. Shoulder motion was not restricted, except for a slight disturbance of internal rotation. MRI and PET-CT revealed a tumor extending to both the ventral and dorsal aspects of the left scapula (Fig. 2A and B). The patient was diagnosed with Hodgkin lymphoma at 25 years of age, which was treated with chemotherapy that included doxorubicin. To prevent doxorubicin-associated cardiotoxicity, we replaced it with actinomycin-D in the VDC-IE regimen. Two years after treatment, PET-CT and MRI (Fig. 2C) revealed no metastasis or local recurrence. The active range of motion of the shoulder was as follows: forward flexion, 90°; extension, 30°; abduction, 60°; external rotation, 10°; internal rotation, S1; and MSTS score, 87%. Case 3 An otherwise healthy 32-year-old woman was referred to our hospital with a suspected malignant tumor of the right scapula. She noticed a prominence around the shoulder 4 months before visiting us and consulted several clinics; however, the cause of the symptoms was not revealed. On the first visit to our hospital in April 2023, she presented with pain in motion and swelling, with slight redness around the shoulder. MRI revealed a tumor with unclear borders and surrounding inflammation on the scapula, eroding the dorsal cortex (Fig. 3A). PET-CT showed a high SUVmax in the dorsal scapular lesion (Fig. 3B) and multiple pulmonary metastases. After four cycles of VDC-IE, PET-CT revealed a reduced accumulation in her multiple lung metastases. Based on the PET-CT results indicating that the metastases were manageable, we chose to treat the scapular lesion with CIRT. CIRT was administered, followed by two additional cycles of VDC/IE. After the 12th of 17 scheduled cycles of chemotherapy (10 months later from the initiation of VDC-IE regimen), the recovery from myelosuppression was significantly prolonged, and follow-up CT revealed that the pulmonary metastases had grown. The chemotherapy regimen was modified to irinotecan (CPT-11) and temozolomide (TMZ) due to these issues. After the fourth cycle of CPT-11/TMZ, she developed fever, severe pain from the axilla to the back, and an exacerbation of dermatitis. Based on the clinical findings, radiation recall dermatitis was therefore suspected. One month of steroid and narcotic medications alleviated her symptoms. Due to the addition of prednisolone to prevent radiation recall, the patient underwent a total of 20 cycles of CPT-11/TMZ, which kept the growth of the patient's lung metastases gradual, even now, three years after starting treatment. Two years after the initiation of treatment, the patient's active range of motion in the right shoulder was as follows: forward flexion, 150°; extension, 30°; abduction, 150°; external rotation, 65°; internal rotation, S1; and MSTS score, 87% (Fig. 3C). The biopsy specimens from the three cases were fixed in 10% neutral buffered formalin at room temperature for 24 h, dehydrated in a graded ethanol series, cleared in xylene and embedded in paraffin. For histological evaluation, 4-µm sections were deparaffinized, rehydrated and stained with Tissue-Tek® Gill's Hematoxylin (cat. no. 8648; Sakura Finetek) and Tissue-Tek® Eosin (cat. no. 9134-4P; Sakura Finetek) at room temperature using a Tissue-Tek Prisma® Plus Automated Slide Stainer (Sakura Finetek) according to the manufacturer's protocol. For immunohistochemical analysis, 3-µm sections were processed using the BOND Polymer Refine Detection system (Leica Biosystems), including the secondary antibody, following the manufacturer's instructions. Briefly, the sections were incubated for 15 min at room temperature with the following ready-to-use antibodies: Mouse monoclonal antibodies against CD99 (clone 12E7; cat. no. IR057; Dako; Agilent Technologies, Inc.), CD3 (clone LN10; cat. no. PA0553; Leica Biosystems), CD20 (clone L26; cat. no. PA0200; Leica Biosystems), CD56 (clone CD564; cat. no. PA0191; Leica Biosystems), CD138 (clone B-A38; code no. 413881; Histofine), chromogranin A (CGA; clone 5H7; cat. no. PA0515; Leica Biosystems), and synaptophysin (clone 27G12; cat. no. PA0299; Leica Biosystems); and a rabbit monoclonal antibody against cyclin D1 (clone EP12; cat. no. PA0046; Leica Biosystems). The sections were then incubated with the pre-diluted secondary antibody for 10 min and counterstained with hematoxylin for 5 min at room temperature. Staining was visualized using a light microscope (Imager A2; Carl Zeiss AG). Histologically, the specimens showed a proliferation of small round cells with scant cytoplasm, which were positive for Periodic acid-Schiff staining and CD99, but negative for epithelial markers. Fig. 3 shows representative specimens of Case 3. Small round cells that overlapped and had hyperchromatic nuclei diffusely proliferated with a palisading pattern around the vasculature and rosette-like formation (Fig. 4A). The immunohistochemistry results were as follows: CD20(−), CD3(−), CD138(−),CD56(−), CGA(−), synaptophysin(−), CD99(+) (Fig. 4B), Cyclin D1(+) (Fig. 4C), and AT1(−). In addition, negative results for WT-1 and calretinin suggested that the tumor was unlikely to be a CIC-rearrangement tumor. Based on the pathological, radiological, and physical findings, the patient was diagnosed with Ewing sarcoma. Only case 3 was analyzed with the GenMine TOP Cancer Genome Profiling System, which detected the EWSR1-FLI1 fusion. The National Health Insurance system in Japan covers limited molecular biological analyses, including fluorescence in situ hybridization. To undergo insurance-covered cancer gene panel testing, patients with solid tumors must meet specific criteria, such as having no available standard treatment or having completed (or are expected to complete) standard treatment. Cases 1 and 2 were not analyzed for fusion genes because they achieved a complete disease-free status with chemotherapy and CIRT. Discussion Ewing sarcoma has been treated using a multidisciplinary approach that includes chemotherapy, surgery, and/or radiotherapy. Ahmed et al (8) demonstrated that there was no difference in local failure rates among local treatment modalities-surgery, radiotherapy, and surgery combined with radiotherapy-for axial non-spine tumors (rib, clavicle, sternum, and scapula). Iwata et al (14) reported that CIRT and chemotherapy provided an acceptable local control rate for patients with tumors of the unresectable Ewing's sarcoma family. These reports prompted us to explore CIRT as a treatment option for the three current patients. Of the three patients, two had multiple lung metastases on their first visit. CIRT was contraindicated for patients with uncontrollable metastasis at our institute; however, the reduction of metastases by the VDC-IE regimen allowed these cases to be treated with CIRT. All three cases showed no local relapse for more than two and half years after CIRT. Scapulectomy and resection of the surrounding muscles are often necessary to treat malignant tumors originating from the scapula. To restore the shoulder function after scapulectomy, various procedures such as prosthesis, graft reconstruction, and humeral suspension have been reported. The humeral suspension technique following scapulectomy has been used for decades; however, its functional results, with MSTS scores of 58.5–64.9%, appear insufficient (7,15,16). The recent Ipponi report demonstrated that custom-made prostheses following total scapulectomy achieved good functional outcomes, with an MSTS score of 24 (80%); however, no patients could perform above shoulder activities (7). The current cases treated with CIRT demonstrated MSTS scores of 70, 87, and 87%, respectively. Notably, Case 3 showed an impressive range of motion with 150° of forward flexion and abduction. Meanwhile, in Case 1, there was 40° of forward flexion and 20° of abduction, in Case 2, these values were 90° and 60°, respectively. The difference in the range of motion likely depends on the surrounding tissues affected by the tumor. In Cases 1 and 2, the tumor invaded the subscapularis muscle adjacent to the thoracic wall, while in Case 3, it did not. Additionally, the tumor in Case 1 also infiltrated the subacromial bursa. These findings may be explained by the range of motion in Cases 1 and 2 being restricted due to adhesion of the thoracoscapular joint, while contracture around the subacromial bursa severely limited the range of motion in Case 1. One of the side effects in radiotherapy is radiation recall dermatitis, as occurred in Case 3. Radiation recall is defined as an inflammatory reaction in a previously irradiated area, triggered by systemic agents, including anti-cancer drugs, and it can occur even months or years after the completion of radiotherapy (17,18). If severe dermatitis develops, the causative agent should be delayed, reduced, or temporarily withdrawn. Physicians should closely monitor the irradiated area following the administration of anticancer drugs. Ewing sarcoma primarily affects children, adolescents, and young adults (19,20). The patients in the present study may be older than expected because of the lack of a pediatric department and the inability to administer chemotherapy to patients under 12 years of age. Several studies have reported that adult patients with Ewing sarcoma have inferior outcomes compared with pediatric patients, which is speculated to be due to fewer cycles of chemotherapy and delayed clinical detection in adults (21,22). To the best of our knowledge, no studies have examined the differences in the effects of radiotherapy between adult and pediatric patients with Ewing sarcoma. One limitation associated with our study includes the fact that the follow-up periods may have been insufficient to fully assess the patients' shoulder function and second malignancy. Bone-related complications, such as pelvic fractures, vertebral compression fractures, and femoral head necrosis, can sometimes occur after CIRT for lesions around the pelvis. Takenaka et al (23) reported that 10 of 27 patients with unresectable pelvic bone sarcoma treated with CIRT developed femoral head necrosis, with two cases occurring more than 5 years after irradiation. Although the scapula is likely at lower risk for bone-related complications in comparison to the pelvic bones due to minimal weight-bearing influence, long-term evaluation of the affected bones is necessary after CIRT. CIRT provides a minimally invasive treatment option for Ewing sarcoma of the scapula, possibly serving as an alternative to surgery. If the tumor does not invade the scapulothoracic and glenohumeral joints or the subacromial bursa, the shoulder function is expected to be preserved after treatment.